Skip to contentW
West Pharmaceutical Services Inc
W
WSTWest Pharmaceutical Services Inc Q1 2023 · 10-Q
Revenue$716.60M$716.60M−0.5% vs Q1 2022 Net Income$140.00M$140.00M−19.4% vs Q1 2022 EPS Diluted$1.85$1.85−19.2% vs Q1 2022 Gross Profit$271,300,000−4.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
West Pharmaceutical Services Inc · CIK 105770 · Engraved from SEC EDGAR
Operating Cash Flow$138,100,000−8.7% Free Cash Flowderived$56,000,000−34.4% Margins · derivedGross margin37.9%−1.7 pt vs Q1 2022
Operating margin21.7%−4.7 pt vs Q1 2022
Net margin19.5%−4.6 pt vs Q1 2022
ended Mar 31, 2023 · filed Apr 27, 2023 · 27 d after period end